Ramosetron

#	Item
1	Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella Add to Reading List Source URL: www.astellas.com Language: English - Date: 2015-05-26 01:47:13 Antiemetics Abdominal pain General practice Syndromes Ketones Irritable bowel syndrome Diarrhea Ramosetron 5-HT3 antagonist Medicine Health Gastroenterology
2	July 17, 2008 ® Astellas Receives a Japanese Marketing Approval for Irribow Japan, July 17, [removed]Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, Add to Reading List Source URL: www.astellas.com Language: English - Date: 2008-09-17 23:44:53 Antiemetics Abdominal pain General practice Irritable bowel syndrome Syndromes Indoles Diarrhea Ramosetron Intestine Medicine Health Gastroenterology